JP2011527317A - Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療 - Google Patents

Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療 Download PDF

Info

Publication number
JP2011527317A
JP2011527317A JP2011517170A JP2011517170A JP2011527317A JP 2011527317 A JP2011527317 A JP 2011527317A JP 2011517170 A JP2011517170 A JP 2011517170A JP 2011517170 A JP2011517170 A JP 2011517170A JP 2011527317 A JP2011527317 A JP 2011527317A
Authority
JP
Japan
Prior art keywords
nogo
antibody
antagonist
seq
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011517170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527317A5 (https=
Inventor
アビラ，バムズ
マシュー クリーブランド，ショーン
アンドリュー ハンブリン，ポール
クマー プリンジャ，ラビンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2011527317A publication Critical patent/JP2011527317A/ja
Publication of JP2011527317A5 publication Critical patent/JP2011527317A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011517170A 2008-07-11 2009-07-10 Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療 Pending JP2011527317A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7987408P 2008-07-11 2008-07-11
US61/079,874 2008-07-11
PCT/EP2009/058832 WO2010004031A2 (en) 2008-07-11 2009-07-10 Novel treatment

Publications (2)

Publication Number Publication Date
JP2011527317A true JP2011527317A (ja) 2011-10-27
JP2011527317A5 JP2011527317A5 (https=) 2012-07-26

Family

ID=41395512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517170A Pending JP2011527317A (ja) 2008-07-11 2009-07-10 Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療

Country Status (5)

Country Link
US (1) US20110268729A1 (https=)
EP (1) EP2323691A2 (https=)
JP (1) JP2011527317A (https=)
CA (1) CA2730473A1 (https=)
WO (1) WO2010004031A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553300A (ja) * 2019-10-24 2022-12-22 ノヴァゴー セラピューティクス アーゲー 新規抗Ｎｏｇｏ－Ａ抗体

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
KR101951220B1 (ko) 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
KR20150036398A (ko) 2012-07-05 2015-04-07 글락소 그룹 리미티드 근육위축가쪽경화증의 치료에서의 항­ｎｏｇｏ­ａ 항체의 최적 투여 섭생
CN119768424A (zh) * 2022-08-22 2025-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
WO2026041734A1 (en) * 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001504088A (ja) * 1996-09-13 2001-03-27 ローヌ―プーラン・ロレ・エス・アー 筋委縮性側索硬化症の治療方法
JP2005535329A (ja) * 2002-08-10 2005-11-24 イェール ユニバーシティ Ｎｏｇｏ受容体アンタゴニスト
WO2007003421A2 (en) * 2005-07-05 2007-01-11 Glaxo Group Limited Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
WO2007046347A1 (ja) * 2005-10-18 2007-04-26 Ono Pharmaceutical Co., Ltd. 筋萎縮性側索硬化症患者の運動神経保護用医薬
WO2007068750A2 (en) * 2005-12-16 2007-06-21 Glaxo Group Limited Immunoglobulins directed against nogo
JP2007537145A (ja) * 2003-12-22 2007-12-20 グラクソ　グループ　リミテッド アルツハイマー病の治療のためのｎｏｇｏａ抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
WO2006071469A2 (en) * 2004-12-02 2006-07-06 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Modulation of the neuroendocrine system as a therapy for amyotrophic lateral sclerosis
AU2007249811A1 (en) * 2006-05-11 2007-11-22 Avicena Group, Inc. Creatine-ligand compounds and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001504088A (ja) * 1996-09-13 2001-03-27 ローヌ―プーラン・ロレ・エス・アー 筋委縮性側索硬化症の治療方法
JP2005535329A (ja) * 2002-08-10 2005-11-24 イェール ユニバーシティ Ｎｏｇｏ受容体アンタゴニスト
JP2007537145A (ja) * 2003-12-22 2007-12-20 グラクソ　グループ　リミテッド アルツハイマー病の治療のためのｎｏｇｏａ抗体
WO2007003421A2 (en) * 2005-07-05 2007-01-11 Glaxo Group Limited Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
WO2007046347A1 (ja) * 2005-10-18 2007-04-26 Ono Pharmaceutical Co., Ltd. 筋萎縮性側索硬化症患者の運動神経保護用医薬
WO2007068750A2 (en) * 2005-12-16 2007-06-21 Glaxo Group Limited Immunoglobulins directed against nogo

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CSNC200900556020; 医学のあゆみ，ｖｏｌ．１８２，ｐ．８６７-８７８（１９９７） *
JPN6013062659; 医学のあゆみ，ｖｏｌ．１８２，ｐ．８６７-８７８（１９９７） *
JPN6013062663; Ｃｏｃｈｒａｎｅ　Ｄａｔａｂａｓｅ　Ｓｙｓｔ　Ｒｅｖ，　２０００；（２）：ＣＤ００１４４７ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553300A (ja) * 2019-10-24 2022-12-22 ノヴァゴー セラピューティクス アーゲー 新規抗Ｎｏｇｏ－Ａ抗体
JP7788996B2 (ja) 2019-10-24 2025-12-19 ノヴァゴー セラピューティクス アーゲー 新規抗Ｎｏｇｏ－Ａ抗体

Also Published As

Publication number Publication date
EP2323691A2 (en) 2011-05-25
CA2730473A1 (en) 2010-01-14
WO2010004031A3 (en) 2010-04-22
US20110268729A1 (en) 2011-11-03
WO2010004031A2 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
CN107172879B (zh) 抗白细胞介素-33抗体及其用途
JP6218810B2 (ja) 卒中後の神経形成を促進するためのセマフォリン−４ｄ結合分子の使用
US20230183341A1 (en) Methods of use of anti-trem2 antibodies
AU2016200267B2 (en) Pain treatment
KR20160065981A (ko) 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
JP2009533456A (ja) 眼疾患処置のためのｉｌ−１抗体の使用
EA037551B1 (ru) Применение молекул, связывающих семафорин-4d, для лечения атеросклероза
JP2011527317A (ja) Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
BR112013032217B1 (pt) uso de um anticorpo anti-nkg2a
US20250084165A1 (en) Methods of use of anti-trem2 antibodies
AU2016356877A1 (en) Binding agonists for treatment of neurological and other disorders
CN104725507A (zh) 用于治疗神经疾病的人抗体及其诊断和治疗用途
JP6538138B2 (ja) Ｈｅｒｖ−ｗエンベロープタンパク質発現関連疾患において再ミエリン化遮断を治療するための化合物
WO2010042640A1 (en) Use of anti-il-20 antibody for treating stroke
US20230391859A1 (en) Anti-transthyretin antibodies and methods of use thereof
WO2012009640A2 (en) B cell depletion for central nervous system injuries and methods and uses thereof
RU2844863C1 (ru) Применение молекул, связывающих семафорин-4d, для лечения синдрома ретта
JP7748728B2 (ja) 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用
JP2023532882A (ja) レット症候群の処置のためのセマフォリン４ｄ結合分子の使用
RU2849860C1 (ru) Применение связывающих cxcl13 молекул для лечения повреждения периферических нервов
WO2025185724A1 (en) Anti-galectin 3 antibodies and their use in epilepsy and related diseases
EP4474395A1 (en) Anti-fas ligand (fasl) antibodies in the treatment of sjs/ten diseases
US20230416399A1 (en) Methods for treating cancer with anti-gd2/gd3 antibodies
CN120981482A (zh) 抗FAS配体（FasL）抗体治疗SJS/TEN疾病
HK1211593B (zh) 用於治疗神经疾病的人抗体及其诊断和治疗用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140326

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150224